GMT

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, April 10, 2024
Novartis, ASH, Tafasitamab, Webcast, Purchasing, EZH1, EDT, Acquisition, Standard of care, BET, Business analyst, EZH2, Ruxolitinib, Exposition, Society, Safety, Anemia, GMT, MorphoSys, JAK, Annual general meeting, Pharmaceutical industry

“Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.

Key Points: 
  • “Now, in 2024, we are pleased that Novartis is committing to the future of our promising pipeline.
  • With its ample resources, additional scientific expertise and global footprint, Novartis can help accelerate pelabresib's potential worldwide.
  • Total revenues for the fourth quarter 2023 were € 59.0 million compared to € 81.6 million for the same period in 2022.
  • The decrease resulted first and foremost from prior year revenues stemming from the execution of an out-licensing agreement with Novartis.

Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Retrieved on: 
Wednesday, April 3, 2024
Webcast, Patient, GMT, EDT

REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.

Key Points: 
  • REYKJAVIK, Iceland, April 03, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will host an audio call with a market update at 12:15 pm GMT / 08:15 am EDT on April 3, 2024.
  • Anil Okay, Chief Commercial Officer, will be providing the update.
  • Information on how to access the webcast is posted on Alvotech’s investor website at https://investors.alvotech.com/events/event-details/market-update-2024-0... .
  • The webcast will be archived and available for replay for 90 days after the event.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

CMR Surgical announces over 20,000 surgical cases completed using Versius

Retrieved on: 
Thursday, March 21, 2024
ICG, Colorectal surgery, CMR, Elective surgery, Nissen fundoplication, CE, Communication, Patient, Contraindication, Hospital, North Hertfordshire, Bleeding, Sale, Cancer, CMR Surgical, General surgery, MD, Thought, Surgeon, Rib cage, Bypass surgery, Pain, GMT, Cholecystectomy, Fatigue, MAS, Dentistry

CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.

Key Points: 
  • CMR Surgical (CMR) – the global surgical robotics business – has today announced that over 20,000 Versius surgical cases have now been completed as the Company works with hospitals and surgeons around the world to bring minimal access surgery to everyone who needs it.
  • The Versius Surgical Robotic System is a small, modular and versatile surgical robot used for soft tissue surgery.
  • Over 75% of hospitals who have adopted Versius are using the system across two or more surgical specialties, leading to some hospitals around the world purchasing more than one system.
  • Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

Faron’s Financial Statement Release January 1 to December 31, 2023

Retrieved on: 
Wednesday, March 13, 2024
Head, Q&A, Survival, Immunotherapy, Patient, Medicine, Standard of care, CMML, Macrophage, Faron Pharmaceuticals, Neoplasm, EET, Rheumatology, PD-1, TME, PR, ASH, AML, Cancer, Johnson & Johnson, Safety, Azacitidine, MDS, BLA, Decitabine, Food, ODD, Nasdaq First North, PD, Tumor microenvironment, Manuscript, CRS, SICAV, MD, Interferon beta-1a, Haematopoietic system, GMT, FDA, AIM, Neurotoxicity, Infection, EUR, Sanofi, SOC, Metabolism, European Hematology Association, EDT, MBA, IPF, Facility, Treasury, Society, Cytokine release syndrome, CPA, Pharmaceutical industry

As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.

Key Points: 
  • As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.
  • Loss for the period for the financial year ended December 31, 2023, was EUR 30,9 million (2022: EUR 28,7 million).
  • In June 2023, Faron conducted a placement of 2,601,510 newly issued treasury shares to investors to raise EUR 6,6 million gross.
  • In October 2023, the Company successfully raised EUR 7,1 million gross through the issuance of 2,491,998 ordinary shares to investors.

Iveco Group announces its Capital Markets Day to be held 14th March 202

Retrieved on: 
Tuesday, March 12, 2024
EXM, EST, ASTRA, Q&A, Iveco, Agriculture, IDV, FPT Industrial, IVG, IVECO, GMT

Iveco Group N.V. (EXM: IVG) announced today that there will be an Iveco Group Capital Markets Day on Thursday, 14th March 2024.

Key Points: 
  • Iveco Group N.V. (EXM: IVG) announced today that there will be an Iveco Group Capital Markets Day on Thursday, 14th March 2024.
  • A live streaming of the Iveco Group Capital Markets Day will begin at 1:30 p.m. CET / 12:30 p.m. GMT / 8:30 a.m. EST on Thursday, 14th March 2024.
  • Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society.
  • Iveco Group employs more than 35,000 people around the world and has 20 industrial sites and 29 R&D centres.

OCP Announces Date of Fourth Quarter and Full Year 2023 Earnings

Retrieved on: 
Thursday, March 21, 2024
Agriculture, Natural Resources, Other Natural Resources, EST, OCP, GMT, Security (finance)

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2024 results on Thursday, March 28, 2024.

Key Points: 
  • OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2024 results on Thursday, March 28, 2024.
  • The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers on the OCP Intralinks portal from 10:00 a.m. EST, 2:00 p.m. Morocco and London time (GMT).
  • OCP senior management will host a conference call to discuss fourth quarter and full year 2023 results at 11:00 a.m. EST, 3:00 p.m. Morocco and London time (GMT), on Thursday, March 28, 2024, for holders of the Company’s bonds, qualified institutional buyers, securities analysts, and market makers.

Exscientia Business and Financial Update for the Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Federal Reserve Bank, Automation, Ovarian cancer, DSM-IV codes, CDK7, Learning, LSD1, Bill, Half-life, UGT1A1, International, Inflammation, Patient, EDT, G&A, Cancer, AI, Bristol Myers Squibb, IND, Medicine, Merck Group, Sumitomo Pharma, PKC, ID, GMT, MALT1, Acute leukemia, Pharmaceutical industry

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below.
  • Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT.
  • This study has the potential to support the ongoing development of ‘539, Exscientia’s LSD1 inhibitor
    In July 2023, Exscientia launched EXCYTE-1, a first-of-its-kind prospective observational study in ovarian cancer.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .

Confluent Unveils Tableflow to Unite Analytics and Operations with Data Streaming

Retrieved on: 
Tuesday, March 19, 2024
Professional Services, Data Management, Data Analytics, Apps, Applications, Technology, Software, Networks, Cloud, Microsoft, Azure, Microsoft Azure, Organization, Software as a service, Data, ServiceNow, Superblock, Central nervous system, Connect, Salesforce, Confluence, IDC, Table, SLA, AWS, Ecosystem, Apache Kafka, SingleStore, Workload, Flink, GMT, CFLT, Squid, CWC, Video game

Confluent Tableflow easily transforms Apache Kafka® topics and the associated schemas to Apache Iceberg® tables with a single click to better supply data lakes and data warehouses.

Key Points: 
  • Confluent Tableflow easily transforms Apache Kafka® topics and the associated schemas to Apache Iceberg® tables with a single click to better supply data lakes and data warehouses.
  • The analytical estate includes data warehouses, data lakes, and analytics engines that power analytics and decision-making and use data streams and historical tables to run queries and different analytical functions.
  • Connectors address the challenges of traditional data architectures that can silo data, decrease data quality, and lead to unplanned downtime.
  • Schema Registry is a crucial component for governing data streams, helping teams enforce universal data standards to ensure data quality and data consistency while reducing operational complexity.

UiPath Unveils New Family of LLMs at AI Summit to Empower Enterprises to Harness Full Capabilities of GenAI

Retrieved on: 
Tuesday, March 19, 2024
Technology, Artificial Intelligence, Other Technology, Data Management, Test automation, Automation, Process mining, UX, Organization, Mining, Q&A, IDP, AEDT, Environment, Trust, EDT, PII, AI, IBM, Document, LLM, GMT, Collection, Context, Partnership, Developer, Sales

UiPath will showcase its latest capabilities at the virtual AI Summit taking place today, March 19 at 10:00 am GMT, 11:00 am EDT, and 3:00 pm AEDT.

Key Points: 
  • UiPath will showcase its latest capabilities at the virtual AI Summit taking place today, March 19 at 10:00 am GMT, 11:00 am EDT, and 3:00 pm AEDT.
  • “Businesses need an assortment of AI models, the best in class for every task, to achieve their full potential.
  • General-purpose GenAI models like GPT-4 struggle to match the performance and accuracy of models specially trained for a specific task.
  • Context Grounding will enhance all UiPath Gen AI experiences in UiPath Autopilots, GenAI Activities, and intelligent document processing (IDP) products like Document Understanding.